• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>RSC Advances >Effects of Osteo-F, a new herbal formula, on osteoporosis via up-regulation of Runx2 and Osterix
【24h】

Effects of Osteo-F, a new herbal formula, on osteoporosis via up-regulation of Runx2 and Osterix

机译：新型草药配方Osteo-F通过Runx2和Osterix的上调 对骨质疏松的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Osteoporosis is characterized by low bone mass and structural weakness, resulting in a high risk of fracture. The aim of this study is to investigate the ameliorative effects of a herbal formula, Osteo-F, containing Schizandra chinensis, Lycium chinensis and Eucommia ulmoides, on osteoporosis. Female ICR mice were randomly assigned to a sham-operated group (Sham) and five ovariectomized (OVX) groups: OVX with vehicle (OVX), OVX with calcium (Ca), and OVX with 1, 10 and 100 mg per kg per day Osteo-F (OF1, OF10 and OF100). Oral administration of Ca or Osteo-F started 7 weeks after OVX and lasted for 13 weeks. The femurs were collected to analyze the bone mineral content (BMC) and bone mineral density (BMD) and bone histology. Blood was collected to examine serum calcium concentration. In addition, the expressions of Runx2 and Osterix in SaOS-2 osteoblast cells were analyzed to confirm the mechanism on osteoblast differentiation. In the present study, Osteo-F treatment significantly restored the low BMC and BMD in the femur. As shown in histological analysis, hyperplasia of the growth plate in the epiphyseal plate was markedly recovered in Osteo-F-treated bone. In addition, serum calcium concentrations were increased with Osteo-F treatment. In the in vitro study, the expressions of Runx2 and Osterix were significantly increased in Osteo-F-treated SaOS-2 osteoblast cells. These results indicate that oral administration of Osteo-F, a newly developed formula, has ameliorative effects on osteoporosis by increasing osteoblast related markers, such as Runx2 and Osterix.
机译：骨质疏松症的特征是骨量低和结构无力，导致骨折的风险很高。这项研究的目的是研究含有五味子，枸杞和杜仲的草药配方Osteo-F的改善作用。 ，对骨质疏松症。将雌性ICR小鼠随机分为假手术组（Sham）和五个卵巢切除组（OVX）组：OVX含载体（OVX），OVX含钙（Ca）和OVX分别为每天每公斤1、10和100 mg Osteo-F（OF1，OF10和OF100）。 Ca或Osteo-F的口服给药从OVX后7周开始，持续13周。收集股骨以分析骨矿物质含量（BMC），骨矿物质密度（BMD）和骨组织学。收集血液以检查血清钙浓度。另外，分析了Runx2和Osterix在SaOS-2成骨细胞中的表达，以证实其在成骨细胞分化中的作用。在本研究中，Osteo-F治疗可显着恢复股骨的低BMC和BMD。如组织学分析所示，在Osteo-F处理的骨中，recovered骨板中生长板的增生明显恢复。此外，Osteo-F处理可增加血清钙浓度。在体外研究中，Osteo-F处理的SaOS-2成骨细胞中Runx2和Osterix的表达显着增加。这些结果表明，口服Osteo-F（一种新开发的配方）可通过增加成骨细胞相关标记（如Runx2和Osterix）来改善骨质疏松症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号